The nurse is teaching a client with chronic heart failure about spironolactone therapy. Which client statement indicates correct understanding?

Digoxin is a cardiac glycoside that inhibits the sodium-potassium ATPase pump to increase intracellular calcium, facilitating positive inotropy. It manages heart failure and tachyarrhythmias, but its therapeutic window is narrow, ranging from 0.5 to 2.0 ng/mL. Toxicity risk is significantly amplified by hypokalemia, as low potassium increases drug binding to myocardial receptors. Severe toxicity can manifest as life-threatening ventricular dysrhythmias or heart block.

Rationale for correct answer

C. A serum potassium level of 2.0 mEq/L indicates severe hypokalemia, which dramatically sensitizes the myocardium to digoxin. Potassium and digoxin compete for the same binding site on the ATPase pump enzyme. When extracellular potassium is significantly low, more digoxin molecules bind to the pump, leading to excessive intracellular calcium and toxicity. This specific electrolyte imbalance is the most common cause of digitalis-induced arrhythmias in clinical practice.

Rationale for incorrect answers

A. An apical pulse rate of 62 beats/min is within the normal range for an adult at rest. While digoxin has negative chronotropic effects, the nurse typically only withholds the medication if the heart rate drops below 60 beats/min. This heart rate does not suggest drug accumulation or an increased risk of toxic manifestations. Continuous monitoring is required, but this finding is currently hemodynamically stable.

B. The serum digoxin level of 1.5 ng/mL is within the accepted therapeutic range of 0.5 to 2.0 ng/mL. This concentration suggests that the medication is providing necessary inotropic support without reaching toxic thresholds in the bloodstream. A level of 1.5 ng/mL is generally considered safe and effective for treating congestive heart failure.

D. A serum calcium level of 9.9 mEq/L is a normal finding, as the reference range is typically 9.0 to 10.5 mEq/L. Although hypercalcemia can potentiate the effects of digoxin and lead to toxicity, this value does not represent an elevation. The client is not at an increased risk of cardiac glycoside complications based on this stable electrolyte profile.

Test-taking strategy

• Identify the core objective: The question asks for a finding that increases the possibility of toxicity, not necessarily a symptom of toxicity itself.
• Compare lab values to standard reference ranges:
  • Potassium: 3.5 to 5.0 mEq/L (Choice 3 is significantly low).
  • Digoxin: 0.5 to 2.0 ng/mL (Choice 2 is normal).
  • Calcium: 9.0 to 10.5 mEq/L (Choice 4 is normal).
• Apply pharmacological principles: Recall that hypokalemia (low potassium) is the primary metabolic disturbance that triggers digoxin toxicity due to competitive binding at the cellular level.
• Analyze nursing assessment: An apical pulse of 62 (Choice 1) is above the standard hold parameter of 60, making it a normal finding.
• Use risk prioritization: When multiple choices involve electrolytes, select the one that has the most profound and direct impact on the medication's safety profile.
• Focus on preventative safety: Recognizing a low potassium level is a proactive nursing action to prevent toxicity before clinical symptoms emerge.

Take home points

• Hypokalemia significantly increases the risk of digoxin toxicity because potassium and digoxin compete for binding sites on the sodium-potassium ATPase pump.
• The therapeutic range for digoxin is narrow (0.5 to 2.0 ng/mL), necessitating frequent blood draws to ensure the patient remains within safe limits.
• Nurses must assess the apical pulse for 1 full minute before administration and withhold the dose if the heart rate is less than 60 beats/min.
• Other electrolyte imbalances that increase toxicity risk include hypomagnesemia and hypercalcemia, both of which can lead to life-threatening cardiac dysrhythmias.

Angiotensin-converting enzyme inhibitors prevent the conversion of angiotensin 1 to angiotensin 2, causing systemic vasodilation and decreased aldosterone secretion. This mechanism results in increased bradykinin levels within the pulmonary vasculature, often precipitating a persistent, non-productive inflammation of the airways. These agents treat hypertension and heart failure but carry risks of angioedema and hyperkalemia.

Rationale for correct answer

B. Inhibition of angiotensin-converting enzyme prevents the breakdown of bradykinin and substance P in the lung tissue. This accumulation triggers a persistent, dry, hacking cough in approximately 5 to 20 percent of patients. Because this effect is often refractory to antitussive medications, it frequently necessitates the permanent discontinuation of therapy. It is the most common reason for switching to an angiotensin receptor blocker.

Rationale for incorrect answers

A. ACE inhibitors are generally associated with gastrointestinal disturbances like nausea or diarrhea rather than decreased bowel motility. Constipation is not a documented or clinically significant side effect of this medication class in human trials. If a patient experiences infrequent stools, other factors or concurrent medications should be investigated

C. While certain antihypertensive classes like beta-blockers or diuretics can impact reproductive health, ACE inhibitors typically do not cause sexual dysfunction. These drugs are often selected as alternatives when a patient experiences such issues on other therapies. They maintain relatively neutral effects on hemodynamics related to sexual performance.

D. ACE inhibitors primarily cause a reduction in systemic vascular resistance without a significant reflexive increase in heart rate. Significant tachycardia is not a standard reaction and might actually indicate an underlying compensatory mechanism for hypotension. Patients are more likely to experience dizziness or orthostatic changes during the initiation phase.

Test-taking strategy

• Identify the specific drug class: Focus on ACE inhibitors (often ending in -pril, such as lisinopril).
• Recall class-specific adverse effects: Distinguish between general side effects and those unique to this mechanism of action.
• Connect the mechanism to the symptom: Recall that ACE is the same enzyme that degrades bradykinin. Inhibiting the enzyme means bradykinin stays in the lungs, causing irritation.
• Evaluate the impact on compliance: The question asks for a "common" reaction that leads to "disruption of therapy." While many side effects exist, the dry cough is the most frequent reason patients cannot tolerate the drug.
• Rule out common distractors:
  • Sexual dysfunction is a common reason for stopping beta-blockers.
  • Constipation is a common side effect of calcium channel blockers (like verapamil).
  • Tachycardia is a reflexive response often seen with hydralazine or other pure vasodilators, but not ACE inhibitors.

Take home points

• The persistent dry cough associated with ACE inhibitors is caused by the accumulation of bradykinin and typically resolves within days of stopping the medication.
• Angioedema is a rare but life-threatening adverse effect characterized by swelling of the tongue and airway that requires immediate emergency intervention.
• Patients on ACE inhibitors must be monitored for hyperkalemia because the suppression of aldosterone leads to decreased renal potassium excretion.
• If a cough becomes intolerable, the healthcare provider will typically transition the patient to an angiotensin receptor blocker, which does not affect bradykinin levels.